Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

Finch Therapeutics

Status and phase

Withdrawn

Phase 2

Conditions

Autistic Behavior

Fecal Microbiota Transplant

Fecal Transplant

Autism Spectrum Disorder

FMT

SPROUT

ASD

Finch

Autism

CP101

Autistic Thinking

Treatments

Drug: CP101

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03829878

CP101-ASD-203

Details and patient eligibility

About

Adolescent autism spectrum disorder subjects with associated GI symptoms will be randomized to receive oral dosing of CP101 capsules in Treatment Group I or matching placebo capsules in Treatment Group II. The purpose of this study is to demonstrate the safety and effectiveness of CP101 in subjects with ASD and associated GI symptoms.

Full description

This is a Randomized Double-Blind Placebo Controlled Study of CP101 (Full-Spectrum Microbiota®) in Children with Autism Spectrum Disorder and Associated Gastrointestinal Symptoms

Sex

All

Ages

5 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or Female ages 5 to 17
Diagnosis of ASD by health care provider
CARS-2 score ≥35 by the study evaluator
1 year history of chronic abnormal bowel function with/without GI symptoms
GSRS/Constipation sub-score ≥3.0, or/and GSRS/diarrhea sub-score ≥3.0, during Screening

Exclusion criteria

Inability to ingest intact capsules.
Change or anticipated change of prescription medications and/or nutrition supplement and/or therapy to treat ASD symptoms
Prior history, evidence, or diagnosis of inflammatory bowel disease or chronic autoimmune GI disease
Below 5th percentile for weight on Centers for Disease Control and Prevention (CDC) growth chart based on age
History of fecal microbiota transplantation (FMT) for any condition, regardless of route of administration within 12 months of Screening, or plan to undergo during the study
History of epilepsy or any other seizure (except febrile seizure) disorder.
Enrollment in any other investigational drug or device study within 8 weeks prior to investigational study medication (CP101/placebo) administration or within 5 half-lives of the last dose of the previous investigational compound, whichever is longer.
Major intra-abdominal surgery within the past 60 days prior to Screening (excluding appendectomy or cholecystectomy) and/or planned invasive surgery/hospitalization during the study.
Use of systemic antibiotics, systemic antiviral, or systemic antifungal (non-topical) for any condition during 8 weeks prior to Screening, or any anticipated use of above for any condition (e.g., frequent otitis media requiring antibiotics) before EOT (Week 24).
Recent change or anticipated change of non-dietary probiotics.
Any clinically significant condition that would jeopardize the safety or rights of the subject, or would confound the results of the study, in the opinion of the Principal Investigator.
Clinically significant laboratory abnormalities at Screening at the discretion of the Principal Investigator.
Pregnant, breast-feeding, or positive pregnancy test at Screening (for females of child-bearing potential) or for sexually active subjects (as determined by the Principal Investigator), who refuses to practice an acceptable form of birth control for the duration of the study.